文献速递脊柱关节炎

抗肿瘤坏死因子治疗期间强直性脊柱炎骨形成的18F-氟化物正电子发射断层扫描成像

Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

研究纳入12例未使用过抗TNF药物的强直性脊柱炎患者,用18F-氟化物PET-CT评估骨形成,其中2例取脊柱活检,10例在抗TNF治疗12周后复查PET。基线所有患者至少有一个轴向PET阳性病灶,活检证实局部类骨质形成;临床应答者肋椎关节和骶髂关节的18F-氟化物摄取在12周后显著下降。

要点

  • 基线时全部12例患者均至少有一个轴向PET阳性病灶。
  • PET阳性病灶活检证实局部类骨质形成。
  • 抗TNF治疗12周后临床应答者肋椎关节和骶髂关节摄取显著下降。

核心结论

  • 18F-氟化物PET-CT可识别强直性脊柱炎患者脊柱和骶髂关节的骨形成,并经组织学证实,且显示抗TNF治疗期间骨形成的变化。

研究设计与样本

  • 纳入12例未使用过抗TNF药物的强直性脊柱炎患者(女性7/12;年龄39岁,SD 11;BASDAI 5.5±1.1)。
  • 基线行18F-氟化物PET-CT,其中2例从PET阳性和PET阴性脊柱病灶取活检。
  • 其余10例在抗TNF治疗12周后行第二次18F-氟化物PET-CT。
  • PET扫描由两名设盲的专家阅片者视觉评分,并用经个体全血活度浓度校正的标准化摄取值(SUVAUC)定量18F-氟化物摄取。
  • 临床应答按24周时国际脊柱关节炎评估协会(ASAS)标准改善≥20%定义。

主要发现

  • 基线时所有患者均显示至少一个轴向PET阳性病灶。
  • 脊柱PET阳性病灶的组织学分析证实局部类骨质形成。
  • PET阳性病灶见于肋椎关节(43%)、小关节(23%)、桥接性韧带骨赘(20%)、非桥接性椎体病灶(14%)和骶髂关节(75%)。
  • 抗TNF治疗12周后,临床应答者肋椎关节18F-氟化物摄取显著下降(平均SUVAUC -1.0;P < 0.001),骶髂关节亦显著下降(平均SUVAUC -1.2;P = 0.03),与非应答者不同。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Excessive bone formation is an important hallmark of AS. Recently it has been demonstrated that axial bony lesions in AS patients can be visualized using 18F-fluoride PET-CT. The aim of this study was to assess whether 18F-fluoride uptake in clinically active AS patients is related to focal bone formation in spine biopsies and is sensitive to change during anti-TNF treatment. METHODS: Twelve anti-TNF-naïve AS patients [female 7/12; age 39 years (SD 11); BASDAI 5.5 ± 1.1] were included. 18 F-fluoride PET-CT scans were performed at baseline and in two patients, biopsies were obtained from PET-positive and PET-negative spine lesions. The remaining 10 patients underwent a second 18F-fluoride PET-CT scan after 12 weeks of anti-TNF treatment. PET scans were scored visually by two blinded expert readers. In addition, 18F-fluoride uptake was quantified using the standardized uptake value corrected for individual integrated whole blood activity concentration (SUVAUC). Clinical response to anti-TNF was defined according to a ⩾ 20% improvement in Assessment of SpondyloArthritis international Society criteria at 24 weeks. RESULTS: At baseline, all patients showed at least one axial PET-positive lesion. Histological analysis of PET-positive lesions in the spine confirmed local osteoid formation. PET-positive lesions were found in the costovertebral joints (43%), facet joints (23%), bridging syndesmophytes (20%) and non-bridging vertebral lesions (14%) and in SI joints (75%). After 12 weeks of anti-TNF treatment, 18F-fluoride uptake in clinical responders decreased significantly in the costovertebral (mean SUVAUC -1.0; P < 0.001) and SI joints (mean SUVAUC -1.2; P = 0.03) in contrast to non-responders. CONCLUSIONS: 18F-fluoride PET-CT identified bone formation, confirmed by histology, in the spine and SI joints of AS patients and demonstrated alterations in bone formation during anti-TNF treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Bruijnen STG, Verweij NJF, van Duivenvoorde LM, et al. Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography. Rheumatology (Oxford). 2018. PMID: 29329443. doi:10.1093/rheumatology/kex448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。